A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of Pf-04447943 On Qtc Interval In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
At a glance
- Drugs PF 4447943 (Primary) ; Moxifloxacin
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Dec 2017 Results assessing safety and tolerability of PF-04447943 across a clinical trial program in 277 patients (Eight phase 1 studies, One phase II and One phase Ib study) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 22 Nov 2016 Status changed from active, no longer recruiting to completed.
- 15 Sep 2016 Status changed from recruiting to active, no longer recruiting.